COSCIENS Biopharma Inc (CSCI)

[mlkrborn]

Surf this segment of the article is worth pasting just in case link doesnt work.
"This brings me to AEterna Zentaris, Inc. (AEZS). AEterna Zentari is a late-stage drug development company specialized in oncology and endocrinology, offers an attractive investment opportunity at its current price per share. In addition to encouraging metrics, as in their price to sales ratio (1.55), the company boasts a priceless $45 million in cash. If there is one event that every investor fears most when investing in development-stage biotech companies, you can’t help but breathe a sign of relief knowing that your investment is unlikely to be hurt by a stock offering in the nearby future. This conclusion is drawn from the company's ample cash reserve as well as their lack of outstanding debt. Perhaps in light of this data, analysts maintain an average target of $2.25 a share, $3.00 at the top.

The company's drug pipeline consists of multiple compounds in preclinical stages to Phase 3 of development. AEterna Zentaris already markets Cetrotide®, the first luteinizing hormone-releasing hormone (LHRH) antagonist treatment approved for in vitro fertilization. Cetrotide® is approved in more than 80 countries worldwide.

Source: aezsinc.com

In Phase 3, the company’s lead oncology compound, perifosine, an orally active ingredient nearly completely bioavailable with antitumor capacities, targets Multiple myeloma and advanced metastatic colorectal cancer. The FDA granted periosine orphan-drug designation in September 2009 as well as Fast Track designation in December 2009.

Then on March 1, 2010, perifosine received a positive opinion for orphan medicinal product designation in the same indication from the Committee for orphan medicinal products of European Medicines Agency. AEterna licensed rights for the compound to Keryx BioPharmaceuticals (KERX) in North America and to Handok Pharmaceuticals Co., Ltd. in Korea. Æterna Zentaris holds the rest of the world rights.

Priced at a discount to where its competitors trade and offering multiple drug pipeline prospects, AEterna Zentaris, Inc. (AEZS) is in position to make the next big move in biotech.

Disclosure: No positions at time of writing"